MedPath

Study of nirgundi and hadjod base formulation on knee joint ostioarthritis

Phase 2
Not yet recruiting
Conditions
Osteoarthritis of knee, unspecified,
Registration Number
CTRI/2022/07/043798
Lead Sponsor
CSIR NEW DELHI HCP
Brief Summary

A CLINICAL STUDY TO EVALUTE THE EFFICACY OF NIRGUNDI AND HADJOD BASE ORAL AND TROPICAL FORMULATION ON KNEE JOINT OF OSTIOARTHRITIS PATIENTS WILL BE DONE ON 60 PATIENTS AS PER OUR INCLUSION AND EXCLUSION CRITERIA ON THE DURATION OF 6 MONTH. AFTER COMPLETION OF TRIAL THE OUTCOME WILL ANALYZED AS PER SUBJECTIVE AND OBJECTIVE PARAMETER.AFTER C.OMPLETION OF THE STUDY WE WILL PUBLISE THE STUDY ON REPUTATE JOURNAL.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Volunteers with affected joints,who are willing to undergo the treatment.
  • Age between 40 -70 years.
  • Individuals who are willing and able to participate for 6 months of duration.
Exclusion Criteria
  • Patients not willing for trial.
  • Patients below the age of 40 years and above 70 years.
  • Patients who have participated in any clinical trial during past 6 months.
  • Subjects with cardiac problems.
  • Subjects with uncontrolled diabetes mellitus Subjects with multiple joint disorders.
  • Subjects with advanced rheumatoid arthritis.
  • Subject advanced knee osteoarthritis.
  • Subjects suffering from major systemic illness necessitating long term drug treatment (R.A, PTB, malignancy etc.) Any other condition which the Investigator thinks may compromise the safety of the subject.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement will be evaluated by objective evaluation of knee joints (affected joint or both joints) (mandatory); X-ray and MRI depending upon availability. It will be done to check the efficacy of the productOSTEOARTHRITIS PATIENT.8 WEEKS
EFFECT ON CHOLEGEN HEALTH8 WEEKS
Secondary Outcome Measures
NameTimeMethod
Other parameters such as Complete Blood Count, ESR, Liver function test, renal function test etc will be evaluated to check safety and any adverse effect on the patient.8 WEEKS

Trial Locations

Locations (1)

OPD NO 213 Surgery Department

🇮🇳

Kangra, HIMACHAL PRADESH, India

OPD NO 213 Surgery Department
🇮🇳Kangra, HIMACHAL PRADESH, India
DR ANIL KUMAR SHARMA
Principal investigator
9805056393
dranilpaprola@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.